Despite Hunan Jiudian Pharmaceutical's inferior earnings outlook, it trades at a market-comparable P/E, risking shareholders' investments and potential investors paying an unnecessary premium if the P/E aligns with the growth outlook.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more